Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Lupin receives USFDA tentative approval for Enzalutamide Tablets
Lupin today announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Enzalutamide Tablets, 40 mg, 80 mg, 120 mg, and 160 mg.
Indian pharma, CDMOs set to gain from US cancer drug supply crunch: Bernstein
Zydus Lifesciences, Lupin and Sun Pharmaceutical Industries could benefit from a US oncology drug supply crunch and India's emerging GLP-1 market opportunity, according to Nandan Kulkarni, Senior Analyst-India Healthcare at Bernstein. He believes Indian biopharma companies are strengthening their role in global healthcare supply chains.
Lupin gains after launching generic hypertension drug in the US
Lupin rose 1.16% to Rs 2,293.10 after launching Azilsartan Medoxomil Tablets, 40 mg and 80 mg, in the United States following approval of its abbreviated new drug application (ANDA) by the US Food and Drug Administration (USFDA).
Stock Alert: HFCL, Lupin, RVNL, Balkrishna Industries
Shares of Kaynes Technology India are banned from F&O trading on 18 June 2026.
Stocks to Watch today: RVNL, HFCL, Gujrat Gas, Hudco, Lupin, Hexware Tech
Stock to Watch today, June 18: ZF Commercial Vehicle Control Systems India, Lemon Tree Hotels, Anik Industries, and Balkrishna Industries are among the top stocks to remain in focus
Stocks to Watch Today: Rail Vikas Nigam, HFCL, Bosch Home Comfort, Lupin, Corona Remedies, Susan... - Moneycontrol.com
Stocks to Watch Today: Rail Vikas Nigam, HFCL, Bosch Home Comfort, Lupin, Corona Remedies, Susan...Moneycontrol.com
Stocks to Watch for June 18: Lupin, HFCL, RVNL, Apollo Hospitals and more
Lupin, HFCL and RVNL have announced key business wins, while Bosch Global Software Technologies plans an OFS in Bosch Home Comfort India. Apollo Hospitals has also settled an RBI compounding case with a ₹17.8 crore payment. Here are stocks to watch ahead of Thursday’s session.
Lupin launches generic hypertension drug in US after regulatory nod
Lupin has launched Azilsartan Medoxomil tablets in the US after securing FDA approval, becoming the exclusive first-to-file generic applicant and gaining 180 days of market exclusivity for the hypertension treatment.
Lupin launches generic hypertension drug in the US
Lupin announced the launch of Azilsartan Medoxomil Tablets, 40 mg and 80 mg, in the United States following approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA).
Stocks to buy: 3 stocks to beat the market in 2026: YES Securities lists Entero, Maruti and Lupin as June stock picks - Mint
Stocks to buy: 3 stocks to beat the market in 2026: YES Securities lists Entero, Maruti and Lupin as June stock picksMint
Bernstein backs Zydus, Lupin and Sun Pharma on innovation shift
Nandan Kulkarni, Director–India Healthcare & Senior Research Analyst at Bernstein, sees strong opportunities in CDMOs, specialty therapies, biosimilars and licensing deals. While favouring Zydus, Lupin and Sun Pharma, he remains cautious on Biocon and Mankind Pharma, and argues that India's shift from generics to innovation could drive the next phase of growth for the pharma industry.
Lupin partners ERN to launch asthma and COPD treatment in Spain
Lupin has partnered Spain's ERN to launch Luforbec for asthma and COPD, extending its respiratory franchise in Europe as the drugmaker continues to build momentum across key global markets.